NCT02176876View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

GS-5745

GS-5745 400 mg administered intravenously

DRUG

Placebo to match GS-5745

Placebo to match GS-5745 administered intravenously

Trial Locations (4)

Unknown

Prague

Balatonfüred

Budapest

Debrecen

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY